Why invest
Market & Opportunities
The European healthcare sector is worth €1.650 trillion, with niche segments showing very high growth and significant entry barriers.
Why the Healthcare Sector
The healthcare sector is characterized by high entry barriers — certifications, regulations and clinical validation — that protect established operators and generate high margins and recurring revenues once market access is achieved.
Demographic trends (aging populations) and the European regulatory framework (European Health Data Space, AI Act) create structural and sustainable long-term opportunities.
Biovalley operates in the most attractive niches: biosimilars with imminent patent expirations, robotics for automating still-manual dangerous processes, medical informatics with very low AI penetration, and orphan drugs with a rapidly expanding market.
Certifications, regulations and clinical validations protect those who have already passed the market access phase
Multi-year contracts, software licenses and maintenance ensure financial stability
The aging of Europe's population creates structural and growing demand for healthcare solutions
EHDS and EU AI Act create standards that favor those already compliant, like BioICT
Biovalley's Markets
Seven market segments with proven growth, each addressed by a specific group company.
| Market Segment | 2023 | 2030 (projected) | CAGR | BIP Company |
|---|---|---|---|---|
| Pharmaceutical robots | $0.2B | $0.35B | 6.7% | BIP (ChemoMaker®) |
| Rare diseases (Italy) | €1.98B | €4.8B | 11.7% | BIP (Orphan Drugs) |
| Biosimilars | €29B | €89B | 17.9% | Serichim |
| Insulin biosimilars | €2.1B | €8.3B | 21.5% | Serichim |
| APIs & intermediates (EU) | €49B | €79B | 6.1% | Serichim |
| Digital health (Italy) | €5B | €19B | 18.1% | CB Sistemi & Multimedia |
| Artificial Intelligence (Italy) | €0.76B | €6.8B | 36.8% | TriesteValley |
Strategic Focuses
Biosimilars & Insulin
Major patent expirations for next-generation insulins (Degludec, Tresiba) open significant opportunity windows. The Serichim-ICGEB platform is ready to position itself in a market worth €8.3 billion by 2030 with a 21.5% CAGR.
Pharmaceutical Robotics
95% of hospitals still manually prepare chemotherapy drugs. First-generation robots required costly structural modifications, limiting adoption. ChemoMaker® CSTD is the plug-and-play solution that overcomes this barrier, aiming to grow beyond the sector's 6.7% CAGR.
AI Healthcare
BIP collaborates with TriesteValley, BIC Incubatori FVG and regional startups to develop vertical AI solutions for private laboratories and clinics, with dedicated HPC infrastructure and GDPR compliance — a critical competitive advantage in the healthcare sector.